Butenafine 1% cream in the treatment of tinea cruris: A multicenter, vehicle-controlled, double-blind trial - 11/09/11
Abstract |
Background: Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris. Objective: We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. Methods: Patients ( n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. Results: Patients in the butenafine group had a higher mycologic cure rate by day 7 (66% vs 13%, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81% vs 13%, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29% vs 5%, p < 0.01) and at 4 weeks after treatment (73% vs 5%, p < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. Conclusion: Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.
(J Am Acad Dermatol 1997;36:S20-4.)
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: Jack L. Lesher, Jr., MD, Section of Dermatology, Medical College of Georgia, 1004 Chafee Ave., Augusta, GA 30912-3190. |
|
0190-9622/97/$5.00 + 0 16/0/79095 |
Vol 36 - N° 2
P. S20-S24 - février 1997 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?